Vera Therapeutics Inc Cl A (VERA) Stock Price, Quote & News

Company Profile

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 770 0077

Website: veratx.com

Address:

2000 Sierra Point Parkway, Suite 1200, Brisbane, United States

diggs24 Jun. 4 at 8:14 PM

$VERA Added 330@$33.95

0 · Reply

biotechworld Jun. 4 at 7:34 PM

$VERA fully loaded...Great news. Possible short squeeze..........

1 · Reply

Wongiiee Jun. 4 at 7:25 PM

$VERA its going to pop again

0 · Reply

droog_botski Jun. 4 at 6:49 PM

$VERA What the hell was that, AI induced trade off Otsuka news ???

1 · Reply

forprofit12 Jun. 4 at 6:26 PM

$VERA any news?

1 · Reply

Irish_lass Jun. 4 at 6:19 PM

$VERA As always

1 · Reply

slickyInvest Jun. 4 at 6:15 PM

$VERA was silly for people to misread fda data as bearish when it was in fact super bullish. Pay the price for misreading while I averaged down and bought some more. Thanks dumb money for letting smart money jump in. That’s why it’s popped now!

0 · Reply

slickyInvest Jun. 4 at 6:13 PM

$VERA popped

0 · Reply

Nabepe Jun. 4 at 2:54 PM

$SPRO As soon as i get my 30% i will increase my position in $VERA

1 · Reply

supplySHOCK Jun. 4 at 9:35 AM

$CORN.X $MNDY $VERA $QSI find

0 · Reply

Vera Therapeutics announces alignment with FDA on earlier ORIGIN 3 eGFR analysis

2026-06-02T16:26:20.000Z - 2 days ago

Raymond James sees unique buying opportunity in Vera after FDA alignment

Jun 2, 2026, 7:00 AM EDT - 2 days ago

Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy

May 21, 2026, 11:00 AM EDT - 14 days ago

Vera Therapeutics Transcript: AGM 2026

2026-05-15T12:28:46.000Z - 20 days ago

Vera Therapeutics price target lowered to $91 from $95 at Evercore ISI

May 8, 2026, 4:05 PM EDT - 27 days ago

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-05-07T20:08:52.000Z - 4 weeks ago

Vera Therapeutics reports Q1 EPS ($1.69), consensus ($1.37)

May 7, 2026, 7:30 AM EDT - 4 weeks ago

Vera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

May 7, 2026, 7:30 AM EDT - 4 weeks ago

Vera Therapeutics Earnings release: Q1 2026

May 7, 2026, 7:30 AM EDT - 4 weeks ago

Vera Therapeutics Quarterly report: Q1 2026

May 4, 2026, 7:30 AM EDT - 4 weeks ago

Vera Therapeutics to Participate in the Bank of America Securities 2026 Health Care Conference

Apr 9, 2026, 8:00 AM EDT - 2 months ago

Vera Therapeutics Proxy statement: Proxy filing

Apr 9, 2026, 8:00 AM EDT - 2 months ago

Vera Therapeutics Proxy statement: Proxy filing

Mar 25, 2026, 7:30 AM EDT - 2 months ago

Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer

2026-03-10T23:05:13.000Z - 3 months ago

Vera Therapeutics upgraded to Outperform from Peer Perform at Wolfe Research

VRTX

2026-03-10T12:03:07.000Z - 3 months ago

Vertex poses ‘no threat’ to Vera Therapeutics’ atacicept, says BofA

VRTX

2026-03-05T14:16:31.000Z - 3 months ago

Vera Therapeutics appoints Hite to Board of Directors

Mar 5, 2026, 9:00 AM EST - 3 months ago

Vera Therapeutics Appoints Christopher Hite to Board of Directors

Mar 3, 2026, 11:10 AM EST - 3 months ago

Vera Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

2026-03-02T11:11:41.000Z - 3 months ago

Vera Therapeutics price target raised to $110 from $90 at H.C. Wainwright

2026-02-26T12:46:30.000Z - 3 months ago

Vera Therapeutics reports FY25 EPS ($4.66), consensus ($4.44)

2026-02-26T12:46:00.000Z - 3 months ago

Vera Therapeutics sees cash runway through atacicept commercial launch

Feb 26, 2026, 7:30 AM EST - 3 months ago

Vera Therapeutics Provides Business Update and Reports Full Year 2025 Financial Results

Feb 26, 2026, 7:30 AM EST - 3 months ago

Vera Therapeutics Annual report: Q4 2025

Feb 26, 2026, 7:30 AM EST - 3 months ago

Vera Therapeutics Earnings release: Q4 2025

Feb 24, 2026, 8:00 AM EST - 3 months ago

Vera Therapeutics to Participate at Upcoming Investor Conferences

2026-01-28T12:35:58.000Z - 4 months ago

Vera Therapeutics appoints Skelton as Chief Commercial Officer

Jan 28, 2026, 7:30 AM EST - 4 months ago

Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer

Jan 28, 2026, 7:00 AM EST - 4 months ago

Vera Therapeutics Slides: Corporate presentation

Jan 13, 2026, 5:15 PM EST - 5 months ago

Vera Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 9, 2026, 7:00 AM EST - 5 months ago

Vera Therapeutics Slides: Corporate presentation

2026-01-07T12:37:21.000Z - 5 months ago

Vera Therapeutics announces atacicept BLA accepted for Priority Review by FDA

Jan 7, 2026, 7:30 AM EST - 5 months ago

Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy

Jan 6, 2026, 2:31 PM EST - 5 months ago

Wells Fargo sees short squeeze ahead: here are three stocks to play it

HRI MTDR

2025-12-21T23:50:11.000Z - 5 months ago

Short Report: Vera Therapeutics bears retreat as stock rallies

MBLY MDGL NGNE

2025-12-19T12:35:35.000Z - 5 months ago

Vera Therapeutics price target raised to $66 from $48 at BofA

2025-12-19T12:25:27.000Z - 5 months ago

Vera Therapeutics price target raised to $95 from $55 at Goldman Sachs

2025-12-19T12:00:44.000Z - 5 months ago

Vera Therapeutics price target lowered to $96 from $99 at JPMorgan

2025-12-16T01:50:18.000Z - 6 months ago

Vera Therapeutics director buys $250K in common stock

2025-12-11T13:26:34.000Z - 6 months ago

Vera Therapeutics price target raised to $33 from $23 at Wedbush

Dec 9, 2025, 8:57 PM EST - 6 months ago

Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock

Dec 8, 2025, 4:01 PM EST - 6 months ago

Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock

Dec 3, 2025, 4:00 PM EST - 6 months ago

Vera Therapeutics Transcript: Citi Annual Global Healthcare Conference 2025

Dec 2, 2025, 8:45 AM EST - 6 months ago

Vera Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 26, 2025, 4:05 PM EST - 6 months ago

Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors

Nov 13, 2025, 1:30 PM EST - 7 months ago

Vera Therapeutics Transcript: TD Cowen Immunology and Inflammation Summit

Nov 10, 2025, 7:29 AM EST - 7 months ago

Vera Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit

Nov 7, 2025, 6:27 PM EST - 7 months ago

Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy

Nov 6, 2025, 4:30 PM EST - 7 months ago

Vera Therapeutics Transcript: KOL Event

Nov 6, 2025, 4:30 PM EST - 7 months ago

Vera Therapeutics Press release: KOL Event

Nov 6, 2025, 4:30 PM EST - 7 months ago

Vera Therapeutics Slides: Corporate Presentation

Nov 6, 2025, 9:51 AM EST - 7 months ago

Vera Therapeutics Announces Positive ORIGIN Phase 3 Data for Atacicept in IgA Nephropathy Presented at ASN Kidney Week 2025 and Published in the New England Journal of Medicine

Nov 5, 2025, 7:29 AM EST - 7 months ago

Vera Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

Nov 5, 2025, 7:00 AM EST - 7 months ago

Vera Therapeutics Earnings release: Q3 2025

Nov 5, 2025, 7:00 AM EST - 7 months ago

Vera Therapeutics Quarterly report: Q3 2025

Oct 22, 2025, 8:00 AM EDT - 8 months ago

Vera Therapeutics to Host an Investor Call and Webcast to Provide an ORIGIN 3 Update on November 6, 2025 at 4:30 pm ET

Oct 17, 2025, 9:12 AM EDT - 8 months ago

Vera Therapeutics Announces ORIGIN 3 Late-Breaking Abstract Selected as Featured Oral Presentation at Opening Plenary Session of ASN Kidney Week 2025

Sep 4, 2025, 9:10 AM EDT - 9 months ago

Vera Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Aug 5, 2025, 12:30 PM EDT - 10 months ago

Vera Therapeutics Quarterly report: Q2 2025

Aug 5, 2025, 12:30 PM EDT - 10 months ago

Vera Therapeutics Earnings release: Q2 2025

Aug 5, 2025, 7:00 AM EDT - 10 months ago

Vera Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Jul 10, 2025, 7:05 PM EDT - 11 months ago

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 11, 2025, 3:15 PM EDT - 1 year ago

Vera Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Jun 4, 2025, 4:05 PM EDT - 1 year ago

Vera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Jun 3, 2025, 6:30 AM EDT - 1 year ago

Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 Million of Term Loans

Jun 2, 2025, 8:45 AM EDT - 1 year ago

Vera shares skyrocket as kidney disease drug succeeds in late-stage trial

Jun 2, 2025, 8:00 AM EDT - 1 year ago

Vera Therapeutics Transcript: Study Result

Jun 2, 2025, 8:00 AM EDT - 1 year ago

Vera Therapeutics Press release: Study Result

Jun 2, 2025, 6:30 AM EDT - 1 year ago

Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy

May 6, 2025, 8:00 AM EDT - 1 year ago

Vera Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

May 6, 2025, 8:00 AM EDT - 1 year ago

Vera Therapeutics Quarterly report: Q1 2025

May 6, 2025, 8:00 AM EDT - 1 year ago

Vera Therapeutics Earnings release: Q1 2025

Apr 3, 2025, 8:00 AM EDT - 1 year ago

Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgAN

Apr 3, 2025, 8:00 AM EDT - 1 year ago

Vera Therapeutics Proxy statement: Proxy Filing

Apr 3, 2025, 8:00 AM EDT - 1 year ago

Vera Therapeutics Proxy statement: Proxy Filing

Mar 4, 2025, 9:10 AM EST - 1 year ago

Vera Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 27, 2025, 8:00 AM EST - 1 year ago

Vera Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference

Feb 26, 2025, 8:25 AM EST - 1 year ago

Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 26, 2025, 8:00 AM EST - 1 year ago

Vera Therapeutics Annual report: Q4 2024

Feb 26, 2025, 8:00 AM EST - 1 year ago

Vera Therapeutics Earnings release: Q4 2024

Jan 13, 2025, 7:30 PM EST - 1 year ago

Vera Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 13, 2025, 7:30 PM EST - 1 year ago

Vera Therapeutics Slides: FY 2025

Jan 7, 2025, 4:05 PM EST - 1 year ago

Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Dec 5, 2024, 7:55 AM EST - 1 year ago

Vera Therapeutics Transcript: 7th Annual Evercore ISI HealthCONx Conference

Nov 13, 2024, 9:30 AM EST - 1 year ago

Vera Therapeutics Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference

Nov 7, 2024, 8:00 AM EST - 1 year ago

Vera Therapeutics Quarterly report: Q3 2024

Nov 7, 2024, 8:00 AM EST - 1 year ago

Vera Therapeutics Earnings release: Q3 2024

Oct 28, 2024, 8:00 AM EDT - 1 year ago

Vera Therapeutics Transcript: Study Result

Oct 28, 2024, 8:00 AM EDT - 1 year ago

Vera Therapeutics Slides: Study Result

Oct 26, 2024, 7:30 PM EDT - 1 year ago

Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024

Oct 2, 2024, 8:00 AM EDT - 1 year ago

Vera Therapeutics Transcript: R&D Day 2024

Oct 2, 2024, 8:00 AM EDT - 1 year ago

Vera Therapeutics Slides: FY 2024

Oct 2, 2024, 6:30 AM EDT - 1 year ago

Vera Therapeutics Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases

Oct 2, 2024, 6:30 AM EDT - 1 year ago

Vera Therapeutics Announces Late-Breaking Oral Presentation of ORIGIN Phase 2b Long-term Results at the American Society of Nephrology Kidney Week 2024

Sep 18, 2024, 9:10 AM EDT - 1 year ago

Vera Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 3, 2024, 7:49 AM EDT - 1 year ago

Load Up on Adobe Stock and These 2 Others This September, J.P. Morgan Says

ADBE CZR KYTX

Aug 8, 2024, 8:00 AM EDT - 1 year ago

Vera Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

Aug 8, 2024, 8:00 AM EDT - 1 year ago

Vera Therapeutics Quarterly report: Q2 2024

Aug 8, 2024, 8:00 AM EDT - 1 year ago

Vera Therapeutics Earnings release: Q2 2024

Jun 11, 2024, 4:01 PM EDT - 2 years ago

Vera Therapeutics Appoints Christy J. Oliger to Board of Directors

Jun 7, 2024, 4:05 PM EDT - 2 years ago

Vera Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Jun 3, 2024, 7:00 AM EDT - 2 years ago

Vera Therapeutics Slides: Corporate Presentation

May 28, 2024, 8:00 AM EDT - 2 years ago

Vera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN)

May 25, 2024, 9:40 AM EDT - 2 years ago

Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress

May 9, 2024, 8:00 AM EDT - 2 years ago

Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

May 9, 2024, 7:00 AM EDT - 2 years ago

Vera Therapeutics Quarterly report: Q1 2024

May 9, 2024, 7:00 AM EDT - 2 years ago

Vera Therapeutics Earnings release: Q1 2024

May 3, 2024, 8:00 AM EDT - 2 years ago

Vera Therapeutics Proxy statement: Proxy Filing

Apr 3, 2024, 8:00 AM EDT - 2 years ago

Vera Therapeutics Proxy statement: Proxy Filing

Apr 3, 2024, 8:00 AM EDT - 2 years ago

Vera Therapeutics Proxy statement: Proxy Filing

Mar 20, 2024, 8:00 AM EDT - 2 years ago

Vera Therapeutics Annual report: Q4 2023

Mar 20, 2024, 8:00 AM EDT - 2 years ago

Vera Therapeutics Earnings release: Q4 2023

Mar 20, 2024, 7:30 AM EDT - 2 years ago

Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Mar 4, 2024, 2:10 PM EST - 2 years ago

Vera Therapeutics Transcript: 44th Annual TD Cowen Health Care Conference

Feb 28, 2024, 4:20 PM EST - 2 years ago

Vera Therapeutics to Participate at the 44th Annual TD Cowen Health Care Conference

Feb 14, 2024, 2:00 AM EST - 2 years ago

Vera Therapeutics Slides: Corporate Presentation

Feb 2, 2024, 8:00 AM EST - 2 years ago

Vera Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Feb 1, 2024, 4:05 PM EST - 2 years ago

Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares in Public Offering of Class A Common Stock

Jan 29, 2024, 11:50 PM EST - 2 years ago

Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock

Jan 25, 2024, 8:00 AM EST - 2 years ago

Vera Therapeutics Transcript: R&D Day 2024

Jan 25, 2024, 8:00 AM EST - 2 years ago

Vera Therapeutics Press release: FY 2024

Jan 25, 2024, 8:00 AM EST - 2 years ago

Vera Therapeutics Slides: FY 2024

Jan 25, 2024, 6:30 AM EST - 2 years ago

Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy

Jan 9, 2024, 6:00 PM EST - 2 years ago

Vera Therapeutics Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

Jan 8, 2024, 8:01 AM EST - 2 years ago

Vera Therapeutics Announces Appointment of Industry Veterans Robert Brenner, M.D. as Chief Medical Officer and William D.

Dec 27, 2023, 8:00 AM EST - 2 years ago

Vera Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Nov 9, 2023, 8:00 AM EST - 2 years ago

Vera Therapeutics Provides Business Update and Reports Third Quarter Financial Results

diggs24 Jun. 4 at 8:14 PM

$VERA Added 330@$33.95

0 · Reply

biotechworld Jun. 4 at 7:34 PM

$VERA fully loaded...Great news. Possible short squeeze..........

1 · Reply

Wongiiee Jun. 4 at 7:25 PM

$VERA its going to pop again

0 · Reply

droog_botski Jun. 4 at 6:49 PM

$VERA What the hell was that, AI induced trade off Otsuka news ???

1 · Reply

forprofit12 Jun. 4 at 6:26 PM

$VERA any news?

1 · Reply

Irish_lass Jun. 4 at 6:19 PM

$VERA As always

1 · Reply

slickyInvest Jun. 4 at 6:15 PM

0 · Reply

slickyInvest Jun. 4 at 6:13 PM

$VERA popped

0 · Reply

Nabepe Jun. 4 at 2:54 PM

$SPRO As soon as i get my 30% i will increase my position in $VERA

1 · Reply

supplySHOCK Jun. 4 at 9:35 AM

$CORN.X $MNDY $VERA $QSI find

0 · Reply

MakeMoneyAZ Jun. 4 at 12:48 AM

$VERA How come this message board isnt popping on this stock

1 · Reply

MakeMoneyAZ Jun. 4 at 12:43 AM

$VERA The dip is here to let all the instituions load up before D-day. We will have our day. I kinda hope it comes before July 7th.

1 · Reply

MakeMoneyAZ Jun. 4 at 12:40 AM

$VERA Locked up 1000+ shares. I aint selling shit

1 · Reply

flamingojack Jun. 2 at 11:51 PM

$VERA https://www.tipranks.com/news/the-fly/raymond-james-sees-unique-buying-opportunity-in-vera-after-fda-alignment-thefly-news

0 · Reply

flamingojack Jun. 2 at 7:40 PM

$VERA hold the line. We’re doing great this is just another drag day for biotech (and beyond, it seems) https://stocktwits.com/news-articles/markets/equity/vera-therapeutics-gains-fda-alignment-for-igan-kidney-drug-but-stock-drops/cZ005wEReD2

0 · Reply

treadingw4ter Jun. 2 at 7:36 PM

$VERA seems like good news today, yet we are tanking 8-10% - any ideas?

1 · Reply

StocktwitsNews Jun. 2 at 4:51 PM

Vera Therapeutics Moves Closer To Full Approval For Kidney Disease Drug After FDA Alignment $VERA https://stocktwits.com/news/equity/markets/vera-therapeutics-gains-fda-alignment-for-igan-kidney-drug-but-stock-drops/cZ005wEReD2

0 · Reply

Irish_lass Jun. 2 at 2:55 PM

$VERA “We are excited for the potential to deliver the first approved therapy targeting both BAFF and APRIL in adults with IgAN, and to bring forward the eGFR analysis to potentially support full approval of atacicept in this indication at an earlier date,” said Marshall Fordyce, M.D., Founder and CEO of Vera Therapeutics.”

0 · Reply

MakeMoneyAZ Jun. 2 at 2:39 PM

$VERA locked up 1000 shares. Wont sell til buyout

1 · Reply

flamingojack Jun. 2 at 12:46 PM

$VERA cow this is great news!!! https://www.investing.com/news/company-news/vera-therapeutics-advances-fda-timeline-for-atacicept-review-93CH-4721499

0 · Reply

Nabepe Jun. 1 at 3:07 PM

$IDYA $SPRO $VERA $KURA bad day across the whole sector

1 · Reply

flamingojack May. 28 at 2:57 PM

$VERA

1 · Reply

Market Cap	2.24B
Revenue (ttm)	0.00
Net Income (ttm)	-299.61M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.15

Volume	2,982,000
Avg Vol	1,145,050
Day's Range	N/A - N/A
Shares Out	71.78M
Stochastic %K	42%
Beta	0.93
Analysts	Strong Sell
Price Target	$78.00